Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Autonomix Medical, Inc. (NASDAQ: AMIX) Just Landed On
The Krypton Street Watchlist This Morning
—Monday, June 22, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Check Out AMIX While It’s Still Early… June 22, 2026 Dear Reader, Pancreatic cancer produces some of the most intractable pain in all of medicine, and for many patients the standard tools — escalating opi-oids, nerve blocks that fade — never fully work. A company in The Woodlands, Texas, has spent the last several years building a way to reach the specific nerves carrying that pain from inside the body's own blood vessels, then confirm in real time that the right nerves were treated. The early human data, presented this spring at a series of major medical meetings, is worth understanding on its own terms. Which is why Autonomix Medical, Inc. (NASDAQ: AMIX) is topping our watchlist this morning—Monday, June 22, 2026. But keep in mind, AMIX has less than 12M shares listed in its float. When companies have small floats like this the potential exists for big moves if demand begins to shift. In fact, analyst Anthony Vendetti of Maxim Group has published a $2 target on AMIX, while healthcare analyst Jeffrey S. Cohen of Ladenburg Thalmann Co. Inc. reportedly holds a $3.60 target. Those figures stand well above AMIX’s recent $0.38 range, What Autonomix Medical, Inc. (NASDAQ: AMIX) is building
Autonomix Medical is a development-stage medical device company working on the peripheral nervous system — the network of nerves outside the brain and spinal cord. Its platform is built around a principle the company sums up as "sense, treat, and verify": a catheter-based system that maps overactive nerve activity, ablates the target nerves with radiofrequency energy, then re-checks the signal to confirm the treatment worked. What makes this technically hard is sensitivity. According to the company's June 2026 corporate presentation, existing cardiac sensing technologies detect activity down to roughly 100 microvolts, while the neuronal signaling traveling through a vessel wall is typically below 5 microvolts — far fainter than current tools can resolve. Autonomix's answer is a proprietary 1-2 mm sensory microchip paired with a custom antenna array, positioned so the signal travels only millimeters before being processed, which the company says preserves signal integrity and allows high-resolution, multi-channel capture for directional targeting. The other half of the idea is verification. Today, the presentation notes, neuronal RF ablation procedures are effective but performed essentially "blind" — physicians lack a way to target, differentiate, or confirm what they treated. The "verify" step is meant to close that gap. The company describes this as a broad platform, with an extensive IP portfolio it puts at more than 120 patents issued and pending.
What the first human trial showed
Autonomix's first-in-human proof-of-concept trial ("PoC 1") enrolled 20 patients at a single clinical site, treating intractable pain associated with pancreatic cancer through transvascular nerve ablation. The presentation is specific about who responded and who didn't, which matters for reading the numbers honestly: of the 20 enrolled, three patients with brachial access showed no improvement, and one patient was enrolled but not treated because an existing celiac trunk stenosis prevented catheter placement. The efficacy results below are drawn from the 16 femoral-access responders. Among those responding patients, the reported pain reduction was substantial and durable. The company's data shows a mean VAS pain-score reduction of 53% at 7 days, 59% at 4-6 weeks, and 66% at the 3-month post-hoc mark — a drop from a mean baseline of 7.81 (severe) down to 2.67 (mild). For context, the presentation cites the clinical literature placing a 20% VAS reduction as the threshold for clinically meaningful pain relief.
The opi-oid-use figures are equally notable: 100% of responders required zero opi-oid use at the 3-month follow-up, and the company reports a 77% improvement in global quality of health among that group. On safety, Autonomix reports no device- or procedure-related serious adverse events, while being transparent that a number of patients succumbed to their underlying disease during follow-up — eight responders before the 3-month mark — which the company attributes to disease progression, not the procedure. Where the program goes next
On the strength of PoC 1, Autonomix has moved to a follow-on "PoC 2" phase, also enrolling 20 patients at a single site. According to the presentation, PoC 2 is designed to refine the procedural protocol, evaluate the company's sensing and RF ablation catheters together, and extend the approach to additional visceral cancers that signal pain through the celiac plexus — stomach, liver, and bile duct — as well as earlier-stage pancreatic cancer. The data is meant to inform the design of a future U.S. clinical trial. The company lays out a regulatory path running from the PoC studies through a U.S. IDE clinical trial to an FDA De Novo submission, targeting potential De Novo clearance in 2028 for the pancreatic cancer-related pain indication. Beyond that lead indication, Autonomix frames the platform as applicable across chronic pain, cardiovascular, and pulmonary conditions.
A spring of external validation
What caught my attention is less any single result than the cadence of independent, peer-facing recognition the data has drawn this year. Autonomix's long-term pancreatic-pain data was selected for a featured abstract and podium presentation at the Society of Interventional Radiology (SIR) 2026 meeting, accepted for presentation at the European Conference on Interventional Oncology (ECIO 2026), accepted at Digestive Disease Week 2026, and accepted for EuroPCR 2026 — one of the leading courses in interventional cardiovascular medicine.
The company was also selected for the Best Innovation competition at CRT 2026 and presented at the LSI USA '26 emerging medtech summit. And in June, the clinical significance of the SIR data was the subject of a "What This Means" segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope in Phoenix, who discussed how the approach to visceral cancer pain differs from existing techniques and its potential applicability beyond pancreatic cancer. Recent Headlines
June 4, 2026 — Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine — See Full Story
May 19, 2026 — Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation — See Full Story
May 18, 2026 — Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation — See Full Story
April 29, 2026 — Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation — See Full Story
April 22, 2026 — Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026 — See Full Story
April 8, 2026 — Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026 — See Full Story
March 11, 2026 — Autonomix Medical to Present at LSI USA '26 — See Full Story
March 5, 2026 — Autonomix Medical Selected for Best Innovation Competition at CRT 2026 — See Full Story
7 Reasons Why AMIX is Topping Our Watchlist This Morning—Monday, June 22, 2026…
1. Low Float: With fewer than 12M shares in its float, AMIX’s small float could have the potential to witness big moves if demand begins to shift. 2. Analyst Coverage: AMIX has published analyst targets of $2 from Maxim Group's Anthony Vendetti and $3.60 from Ladenburg Thalmann's Jeffrey S. Cohen, figures that stand above the company's recent $0.38 range. 3. Human Data: AMIX reported mean pain-score reductions of 53% at 7 days, 59% at 4–6 weeks, and 66% at the 3-month mark among responding patients in its first human study. 4. Novel Platform: AMIX has developed a catheter-based "sense, treat, and verify" system designed to identify, treat, and confirm targeted nerve activity in real time. 5. Clinical Expansion: AMIX has already advanced into its PoC 2 phase, which is designed to refine the procedure and evaluate additional visceral cancer pain indications. 6. Conference Recognition: AMIX data was selected for presentations at SIR 2026, ECIO 2026, Digestive Disease Week 2026, and EuroPCR 2026, placing the program before multiple major medical audiences. 7. Patent Portfolio: AMIX reports an intellectual property portfolio consisting of more than 120 patents issued and pending. Check Out AMIX While It’s Still Early…
Whether your attention is drawn to the early human data, the company's "sense, treat, and verify" technology, the advancement into PoC 2, or the more than 120 patents issued and pending across the platform, there is no shortage of developments worth following at AMIX. The company has already placed its clinical results before major medical audiences at SIR 2026, ECIO 2026, Digestive Disease Week 2026, and EuroPCR 2026, while continuing to expand its clinical program and refine its technology. At the same time, with fewer than 12M shares in its float and analyst targets that stand above its recent $0.38 range, AMIX is a name that could attract attention from both the medical community and market participants alike. As always, do your own homework, review the data for yourself, and focus on the facts. The story surrounding AMIX is still developing, and the coming milestones could provide additional insight into where the program goes from here. We have all eyes on AMIX this morning. Take a look at AMIX while it’s still early. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter |
No comments:
Post a Comment